Welcome to the e-CCO Library!

DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. Harrow*1, C. Skinner1, T. Hoque1, A. Ibarra1, J. Lindsay1, 2

Created: Friday, 22 February 2019, 9:49 AM
DOP069: Dose optimization using drug and antibody levels can benefit 50% patients prescribed anti TNF therapy compared to empiric dose adjustment
Year: 2016
Source: ECCO'16 DOP
Authors: Harrow P.
anti-TNF agents, therapeutic drug monitoring
Files: 1
DOP069: Improved quality of care quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Atreja Ashish
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP069: Improved quality of care and quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Atreja1*, E. Otobo1, E. Szigethy2, H. Shroff1, H. Chang1, L. Keefer1, J. Rogers1, T. Ullman1, J.F. Marion1, B. Cohen1, E. Maser1, S. Itzkowitz1, J.-F. Colombel1, B. Sands1

Created: Thursday, 21 February 2019, 9:14 AM
DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centers
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cremer A.*1, Liefferinckx C.1, De Vos M.2, Rahier J.-F.3, Baert F.4, Moreels T.5, Macken E.5, Louis E.6, Devière J.1, Van Gossum A.1, Vermeire S.7, Franchimont D.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP069: Natural history of dysplasia and colorectal cancer in IBD patients in Belgium tertiary care centers
Year: 2017
Source: ECCO'17 Barcelona
Authors: Cremer A.
Natural history, Dysplasia, UC colorectal cancer surveillance
Files: 1
DOP06: Antibiotics as a risk factor for older onset IBD: A population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Faye, A.(1);Allin, K.(2);Iversen, A.(2);Agrawal, M.(3);Faith, J.(4);Jean-Frederic , C.(3);Jess, T.(2);
Created: Friday, 11 February 2022, 3:52 PM
DOP06: Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Junmei Cairns
Created: Friday, 14 July 2023, 2:22 PM
DOP06: Deep characterization of IL-23 pathway in different gut segments and associated plasma biomarkers in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cairns, J.(1)*;Monkley, S.(2);Tian, S.(3);Angermann, B.(2);Liu, Z.(4);Öberg, L.(5);Muthas, D.(2);Cabrera, C.(6);Rapsomaniki, E.(7);Fernández Llaneza, D.(7);Olsson, M.(8);Paraskos, J.(9);Ellison, G.(10);Khan, E.(11);Duncan, E.A.(12);Neisen, J.(13);Gehrmann, U.(5);Chamberlain, C.(3);
Created: Friday, 14 July 2023, 10:43 AM
DOP06: Development of simplified scoring system to predict two-year clinical remission of patients with Ulcerative Colitis after treatment with vedolizumab
Year: 2024
Source: ECCO'24 Stockholm
Authors: Chaemsupaphan, Thanaboon
Created: Tuesday, 30 April 2024, 5:03 PM
DOP06: Dynamic shifts in the balance of gut homing Treg and Th17 cells play a critical role in ulcerative colitis and may predict response to vedolizumab therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Hermangild Kottoor*1, Z. Kassam1, P. Pavlidis1,2, E. Alberts1, H. Ibraheim1,2, L. Constable1, J. Digby-Bell1, D. Warren2, S. Odukwe2, M. Samaan2, P. Irving2, J. Sanderson2, N. Powell1,2

Created: Friday, 22 February 2019, 9:41 AM
DOP06: Histologic activity in Ulcerative Colitis patients achieving endoscopic healing is associated with higher rate of relapse and a distinct mucosal microbial and transcriptional profile
Year: 2021
Source: ECCO'21 Virtual
Authors: Hernandez-Rocha, C.(1);Turpin, W.(2);Nayeri, S.(3);Borowski, K.(3);Stempak, J.(3);Conner, J.(4);Silverberg, M.S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP06: Non-invasive identification of adherent-invasive E. coli in patients with Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 5:40 PM
DOP06: Non-invasive identification of adherent-invasive E. coli in patients with Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Anthony Buisson
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP07 Long-term results of 4.5 years of faecal microbiota transplantation for treatment of refractory ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Uygun1, M.F. Karakaya1, H. Erdal1, G. Celebi1, Y.S. Sakin1, C. Artuk2, K. Ozturk1, M. Gulsen1

Created: Thursday, 30 January 2020, 10:12 AM
DOP070: Development and pilot of an index to identify young people with Inflammatory Bowel Disease at risk of psychological morbidity
Year: 2018
Source: ECCO'18 Vienna
Authors: Lees Rupert T
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP070: Development and pilot of an index to identify young people with inflammatory bowel disease at risk of psychological morbidity
Year: 2018
Source: ECCO '18 Vienna
Authors:

R.T. Lees1*, A.J. Brooks1, G. Rowse2, P. Narula3, P. Norman4, A.J. Lobo1

Created: Thursday, 21 February 2019, 9:14 AM
DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Alfaro I.*1, Masamunt M.1, Planell N.2, Lόpez-García A.1, Castro J.1, Gallego M.1, Barastegui R.1, Giner A.1, Vara A.1, Salas A.2, Ricart E.1, Panés J.1, Ordás I.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP070: Endoscopic response to induction therapy with TNF inhibitors is the best predictor of long term mucosal healing in Crohn’s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Alfaro I.
Crohn's disease, Disease activity indices, Adalimumab, Infliximab, Colonoscopy
Files: 1
DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in ulcerative colitis patients from GEMINI 1
Year: 2016
Source: ECCO'16 DOP
Authors: Roblin X.
Ulcerative Colitis, therapeutic drug monitoring, vedolizumab
Files: 1